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Thyroid hormones (THs) are essential for fetal and post-natal nervous system development
and also play an important role in the maintenance of adult brain function. Of the two major
THs,T4 (3,5,3′,5′-tetraiodo-l-thyronine) is classically viewed as an pro-hormone that must be
converted toT3 (3,5,3′-tri-iodo-l-thyronine) via tissue-level deiodinases for biological activity.
THs primarily mediate their effects by binding to thyroid hormone receptor (TR) isoforms,
predominantlyTRα1 andTRβ1, which are expressed in different tissues and exhibit distinc-
tive roles in endocrinology. Notably, the ability to respond toT4 and toT3 differs for the two
TR isoforms, with TRα1 generally more responsive to T4 than TRβ1. TRα1 is also the most
abundantly expressedTR isoform in the brain, encompassing 70–80% of all TR expression
in this tissue. Conversion of T4 into T3 via deiodinase 2 in astrocytes has been classically
viewed as critical for generating local T3 for neurons. However, deiodinase-deficient mice
do not exhibit obvious defectives in brain development or function. Considering that TRα1
is well-established as the predominant isoform in brain, and that TRα1 responds to both
T3 and T4, we suggest T4 may play a more active role in brain physiology than has been
previously accepted.
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INTRODUCTION
Thyroid hormones (THs) are synthesized by the thyroid gland and
are critical regulatory molecules with important roles in verte-
brate physiology and development, including fetal and post-natal
nervous system development and the maintenance of adult brain
function (1, 2). The TH requirement for development is most
apparent in the central nervous system (CNS) where severe TH
deficiency in fetal and neonatal periods results in cretinism, a
disease characterized by mental retardation, deafness, and ataxia;
these consequences are irreversible if not treated soon after birth
(3–5). Additionally, untreated hypothyroidism in the adult is
associated with severe intellectual defects, abnormal balance and
defects in fine motor skills, spasticity, and deafness (6). Correct-
ing TH deficiencies is critical for normal brain development and
function.
Thyroid hormones mediate CNS effects primarily through thy-
roid hormone receptors (TRs), members of the nuclear hormone
receptor family (4, 7, 8). TRs bind to the DNA regulatory regions
of target genes to activate or repress transcription through inter-
actions with accessory proteins known as coregulators. There are
two major THs, which bind to and activate TRs: T3 (3,5,3′-triiodo-
l-thyronine) and T4 (3,5,3′,5′-tetraiodo-l-thyronine, also known
as thyroxine). T4 differs from T3 by an additional iodine located
at the 5′-position of the first thyroxine ring. T3 has been assumed
to be the active form of TH, as T3 binds to TRs with a greater
affinity than T4. In this model, T4 is thought to simply act as
a pro-hormone, existing only to be circulated in the serum and
converted at the tissue-level to T3 through an enzymatic reaction
involving the removal of the 5′-iodine atom from T4 by local deio-
dinases (9, 10). Nonetheless, it is notable that most of the TH
produced under normal conditions in the thyroid is secreted in
the form of T4 and steady-state serum concentrations of T4 are
many fold greater than those of T3 (11–14). Notably, iodine intake
is important for the maintenance of both of these TH levels in cir-
culation. In fact, during gestation and lactation in females, double
the normal iodine intake is required to maintain adequate T3 and
T4 in circulation to ensure normal fetal development (15, 16).
Under conditions of low iodine intake, the serum T3/T4 ratio is
somewhat increased reflecting the reduced abundance of iodine
atoms (16). Although the ready availability of dietary iodized salt
has largely eliminated these iodine deficiencies for school children
in most developed countries today, these advances are often not
adequate for pregnant and lactating women (17).
Indeed the primary TH crossing the adult blood–brain barrier
(BBB) is believed to be T4; therefore, the adult brain may have
access to sufficiently high levels of T4 to allow for direct binding
to and transcriptional activation of TRs (18, 19). In fact, we know
that both T4 and T3 binding by TRs lead to very similar struc-
tural changes in the receptor (12). Several reports have also shown
that T4 exhibits non-genomic effects by interacting with integrin
cell membrane receptors (20). These studies suggest that T4 may
exhibit a greater role in physiology than merely acting as a pro-
hormone. Therefore, the precise role of T4 as a pro-hormone and
whether T4 might function directly as an active hormone in the
CNS, remain incompletely answered questions.
T4 SYNTHESIS, TRANSPORT, AND AVAILABILITY IN THE
BRAIN
Determining the effective cellular concentrations of T4 and T3
in the brain, or in any tissue, is difficult due to the complexities
of TH synthesis, transport, and regulation. Vertebrates have devel-
oped multiple mechanisms to ensure delivery of appropriate levels
of TH to peripheral tissues such as the brain. These include reg-
ulation of secretion of THs from the thyroid into serum (21, 22),
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FIGURE 1 |Thyroid hormone synthesis. The thyroid gland makes both T4
and T3, although T4 predominates. The hypothalamus senses low TH in the
circulation and responds by stimulating synthesis and secretion of TRH
(thyroid releasing hormone), which in turn circulates and stimulates
synthesis and secretion of TSH (thyroid stimulating hormone) by the
pituitary. Circulating TSH then increases T4 and T3 production by the thyroid
and ultimately in the circulation. Tissue-specific deiodinases (“DIO”) are
expressed in peripheral tissues such as brain astrocytes to increase local
concentrations of T3 from circulating T4. However, we propose that T4 may
also act directly on TRs to regulate gene transcription in neurons in the
absence of deiodinase 2 conversion to T3.
control of free versus bound levels of THs determined by reversible
binding to serum-binding proteins (22), cell-specific expression of
TH cell membrane transporters (23, 24), and finally intracellular
deiodination of T4 to form T3 [(22, 25); Figure 1].
Transplacental TH transfer from maternal to fetal circula-
tion is particularly important in vertebrate CNS development
[reviewed by Ref. (26)] to ensure appropriate levels of TH are
available to the fetus throughout development (16). Throughout
the first trimester when TH levels are solely obtained through
maternal transfer, free T4 levels are high in the fetus, similar to
levels of biologically active T4 in adults, whereas fetal concen-
trations of T3 are at least 10× lower than T4 (16). Notably, T3
levels in the fetal cerebral cortex increase somewhat between 12
and 20 weeks PMA (post-menstrual age) when placental deio-
dinase 2 levels increase (see below), although maternal serum
levels of T3 are still low. Both T4 and T3 in the fetus continue
to be transferred from maternal origins through the placenta
until half-way through pregnancy when endogenous THs are pro-
duced by the fetal thyroid. However, because fetal T4 synthesis is
elevated over that of T3 for several weeks at this time, it is possi-
ble that an additional window in development exists where fetal
circulating T4 is quite high and may act as an active hormone
with TRs (16).
Outer ring 5′-monodeiodination via cell-specific deiodinases
converts a small fraction of the normal serum T4 pool to T3 (10,
22). Deiodinase 2 is the primary enzyme responsible for intra-
cellular conversion of T4 into T3 in most local tissues including
brain, whereas deiodinase 1 is found primarily in the liver (25,
27). Deiodinase 2 is only expressed in selected cell types within the
CNS: astrocytes and tanycytes. These are both glial cell-derived and
are located in the hypothalamus (28–30). The other deiodinase
enzyme expressed in the CNS is deiodinase 3, selectively expressed
in neurons. Deiodinase 3 inactivates both T4 and T3 by inner ring
deiodination to rT3 and T2 so as to down-regulate local TH con-
centrations and protect the neuron from supraphysiological levels
of TH. Currently it is believed that astrocytes generate active T3
from circulating pro-hormone, T4, whereas neurons degrade both
T4 and T3 to inactive rT3 and T2, respectively, and thereby regulate
local TH availability within the brain. When levels of TH are low,
deiodinase 2 levels in brain increase and contrastingly when there
are high levels of TH, deiodinase 3 levels increase (19, 30, 31). This
balancing act protects the brain from the detrimental effects of
hyper- or hypothyroidism.
T3 concentrations equilibrate rapidly in peripheral tissues such
as the liver and kidney but appear to take longer to equilibrate in
the brain. In general, TH concentrations in the CNS are approx-
imately 20% that of serum concentrations (32); this is likely due
to the added complexity of TH transport across the BBB, which is
comprised of the endothelial cells of brain capillaries surrounded
by astrocyte end feet. To enter the brain, the THs cross the BBB of
the choroid plexus via the MCT8 or OATP1C1 TH transporters.
T4 is thought to predominately enter the CNS in preference to T3
as the majority of BBB TH transporters exhibit greater affinities
for T4 transport [(19, 33); Figure 2]. As mentioned above, after T4
is taken up into astrocytes likely by OATP1C1, deiodinase 2 can in
turn convert it locally to T3. Finally, the astrocyte-generated T3 can
enter neuronal cells via the MCT8 transporter to bind and activate
TRs. Therefore, it is intriguing that the T4-activating deiodinase
is not expressed in the neurons themselves, where the relevant
TRs are located, but in the astrocytes. T4 and/or T3 also enter the
CNS directly via gaps in the end feet of the astrocytes, which do
not completely cover the capillaries in contact with the interstitial
spinal fluid (34).
DIFFERENT TR ISOFORMS DIFFER IN THEIR ABILITY TO BIND
TO T4
Thyroid hormones bind TRs, ligand-regulated transcription fac-
tors, which bind to specific target DNA sequences and repress
or activate target genes through the recruitment and release of
accessory proteins. TRs contact their DNA-binding elements as
protein dimers, heterodimerizing with another member of the
nuclear receptor family, RXRs (primarily Retinoid X Receptors),
or homodimerizing with themselves (35–39). TRs exhibit bimodal
regulation, typically binding corepressors to repress transcription
of target genes in the absence of TH, but releasing corepressors
and recruiting coactivators to activate transcription of these “pos-
itive response” target genes in the presence of TH (40, 41). These
corepressor and coactivator proteins alter the chromatin template
or interact with the general transcription machinery to produce
the appropriate transcriptional outputs. However, many TR target
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FIGURE 2 | Entry ofTH into brain via the blood–brain barrier. TH
can enter neurons by two pathways. The first is by crossing the
endothelial cells of the blood–brain barrier (BBB) by the OAT1P1C
transporter to enter astrocyte end feet (in red). After entering
astrocytes, T4 can be converted into T3 via deiodinase 2, to enter the
neuron (in blue) by the MCT8 transporter. Circulating T4 and T3 may
also enter neurons (and astrocytes) directly via these transporters
through gaps in the astrocyte end feet. Oligodendrocytes (purple),
which express TRs, are also known TH cell targets in the CNS. There
is also evidence of as-yet unknown TH transporters in the brain; the
TH transporters, and their known preferences for T4 or T3, are
indicated in color codes on the right.
genes display the opposite properties in that they are expressed in
the absence of TH and are repressed in the presence of TH; the
molecular mechanisms involved in this “negative response” is not
well-understood.
Thyroid hormone receptors are encoded by two distinct genetic
loci, denoted THRA and THRB, which are each expressed as
alternatively spliced mRNAs to create additional receptor diver-
sity [reviewed in Ref. (42)]. Two of the major TR isoforms are
referred to as TRα1 and TRβ1; both bind TH and yet exhibit dis-
tinct biological roles [reviewed in Ref. (43)]. TRα1 is expressed
early in embryonic development and then widely in adults whereas
TRβ1 is expressed later in embryonic development and exhibits a
more restricted tissue-expression pattern in adults (31, 44–49).
Genetic disruption in mice of TRα1 or TRβ1 indicates that these
isoforms have somewhat overlapping, yet distinct roles in normal
physiology (45–47, 49, 50).
These two different TR isoforms differ in their ability to respond
to T4, with TRα1 generally exhibiting a much stronger response
to T4 than TRβ1. We suggest that different cell types may modu-
late their relative ability to respond to T4 versus T3 by altering the
relative abundance of different coactivators and corepressors that
have distinct responses to T4 and T3, raising the possibility that T4
may be able to function as a direct-acting hormone agonist with
TRα1 (Amy C. Schroeder and Martin L. Privalsky, unpublished
observations).
TRα1 EXPRESSION IN THE BRAIN
Notably, TRα1 encompasses 70–80% of all TR expression in
the adult vertebrate brain (2) and TRα1 is present in nearly all
neurons (51). Intriguingly, TRα1 is also the predominating TR
isoform early in fetal brain development (detected by 8.1 weeks
and increasing until 13.9 weeks post-menstrual age). Critical roles
in CNS development are known to be mediated by TRα1 includ-
ing TH-dependent oligodendrocyte differentiation (52). If TRα1
is inactivated, the number of mature oligodendrocytes after T3
treatment is decreased (52). The commitment of these cells as
oligodendrocytes is therefore believed to be linked to cell-specific
TRα1 expression while the availability of TH regulates the tim-
ing of differentiation (52). In fact, maturation of several cell types
in the brain in development may depend on specific windows
of TRα1 expression and involve a complicated interplay between
TRs, THs, and coregulators (2). Additionally, TRα1 is known to
exhibit important roles in later stages of neurodevelopment and
its expression persists in adult neurons. Therefore, it is interesting
that expression of the TRα1 isoform predominates in both fetal
and in adult brain at the same times when free T4 levels appear to
be at biologically active levels (16), suggesting windows in brain
development may exist where T4 may act on TRα1.
DEIODINASE 2-DEFICIENT MICE EXHIBIT NORMAL CNS
DEVELOPMENT AND FUNCTION
As noted above, deiodinase 2 expression does not overlap TR
receptor expression in the brain. Deiodinase 2 is expressed instead
in astrocytes whereas the TRs are expressed in neurons along with
deiodinase 3 [(28, 29); Figure 2]. The current theory therefore
suggests astrocytes are involved with T4 uptake from capillaries to
subsequently generate a source of locally generated T3. Conversion
of T4 into T3 via deiodinase 2 in astrocytes has been estimated to
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produce as much as 80% of the T3 bound to the TRs in the brain
(18), suggesting astrocyte deiodinase 2 is important for generating
local T3 concentrations. Therefore, many argue that deiodinase 2
likely plays a critical role in developing brain by providing the nec-
essary amount of T3. If this were in fact the case, one would predict
the absence of deiodinase 2 would result in detrimental defects in
CNS development similar to that seen in hypothyroidism.
However, the Galton lab produced a deiodinase 2-deficient and
a deiodinase 2/deiodinase 1 dual-deficient mouse (KOs) without
any evident defects in brain development or function (27, 53). The
deiodinase KO mice demonstrated slightly elevated circulating T4
and TSH levels, and normal thyroid-secretion of T3 but no tissue-
level production of T3 from T4 (27). Notably, these mice did not
display any signs of hypothyroidism and have no gross physiolog-
ical or behavioral abnormalities (27). The deiodinase KO was also
combined with an MCT8 TH transporter knockout (54, 55); this
combination resulted in minor neuronal defects mostly noted by
decreased expression of genes in the neural cortex, which are usu-
ally positively regulated by T3, however, most neural development
and function was normal. KO mice studies suggest that T3 trans-
port into the brain and local conversion of T4 to T3 in the brain
are not essential for normal brain function in mice, and suggest
that CNS T3-defects do not produce syndromes as severe as that
seen in the hypothyroid mice (27).
Many suggest that there might be compensation in the deiod-
inase KO mice through the absorption of more T3 directly from
circulation via the MCT8 transporter in endothelial cells of the
BBB, but it should be again noted that the parallel transporters
such as OATP1C1 and OATP2 favor T4 transport (56, 57) and it
is unlikely that T3 can be transported into the brain at rate equiv-
alent to T4 transport. We suggest that in the absence of available
T3, T4 can act as an active TH in the brain working on, most likely,
TRα1. Interestingly, in the absence of deiodinase 1 and 2, positively
regulated TH genes in the cerebral cortex remain unaffected but
negatively regulated TH genes appear to be impaired in a way that
parallel the hypothyroid mice (27, 58). Perhaps in the absence of
deiodinase 2, T4 can act as an active hormone in brain cells to acti-
vate positively regulated TH genes, but not to repress negatively
regulated TH genes.
It should be noted that humans with MCT8 mutations display
severe neurodevelopmental defects with psychomotor retardation
and abnormal serum TH levels (57, 59)). Contrastingly, MCT8 KO
mice mimic the human MCT8 mutations in their thyroid pheno-
type but display no obvious brain developmental defects (57, 59).
It is therefore possible that the need for locally produced T3, and/or
the presence of alternative T3-specific transporters, differ in mice
and in humans (55).
TR COREGULATORS AND THE BRAIN
T4 efficiently recruits many coactivators to TRα1, with certain
well-established TR coactivators (SRC1 and TRAP220) exhibiting
a T4 response equal or near equal to that induced by T3 (Amy
C. Schroeder and Martin L. Privalsky, unpublished data). SRC1
mRNA is expressed in many tissues during development including
the CNS (60). TRAP220 is also expressed in the developing brain
and is thought to play a regulatory role in the process of cell prolif-
eration and differentiation, in learning, and in memory formation
(61). The widespread expression of TRAP220 in the developing
brain appears to parallel TRα1 expression. Therefore, CNS devel-
opment correlates with a high level of expression of TRα1 together
with TRAP220 and/or SRC1 and may provide an opportunity for
T4 to directly regulate gene transcription. CNS cell-specific differ-
ences in TR isoform and cofactor levels or function are likely to
contribute to differences in T4 hormone response and may suggest
a means by which the T4 sensitivity of a given CNS cell type can
be regulated in response to internal or external signals.
A POSSIBLE DIRECT ROLE FOR T4 IN BRAIN: ARE THERE
CONTEXTS IN THE BRAIN IN WHICH T4 IS A DIRECT-ACTING
TRα1 AGONIST?
Several recent studies have led to the view that T4 exhibits non-
genomic roles that do not require conversion to T3 (20) but which
have not challenged the general view that T3, not T4, is the only
direct, biologically relevant agonist for nuclear TR function. Our
own experiments indicate that TRα1 has the potential to act as a
dual sensor of both T4 and T3 (Amy C. Schroeder and Martin L.
Privalsky, unpublished observations).
Although the effective concentration of T4 in the brain is dif-
ficult to determine, it is plausible that T4 levels are sufficient to
induce activation of TRα1-regulated genes in the brain even in
the absence of T3. We suggest that the normal mix of T4 and
T3 in the brain may actually confer a mixed T4/T3 transcription
response mediated primarily by TRα1, together with a more pure
T3 response mediated primarily by TRβ1. Notably, mice in which
both deiodinase 1 and 2 have been genetically ablated, and thus
lack astrocyte deiodinase conversion of T4 to T3, display only very
mild defects in their physiological with little to no neurological
defects (27). If, as indicated by these knockouts, T4 is not absolutely
required in its traditional role as a pro-hormone, the dominance
of T4 to T3 in the circulation and transport into the CNS may
instead reflect a novel role of T4 as a direct-acting hormone and
this direct role may be helping to ameliorate the effects of the
deiodinase knockouts in the CNS.
In conclusion, TH endocrinology in the CNS is tightly regulated
at multiple tiers. Negative feedback loops in the hypothalamus and
the pituitary control T3 and T4 output by the thyroid gland itself.
Further, multiple phenomenon functions together to modulate
the transport of circulating TH through the BBB, and multiple
transporters act together to directly alter TH availability in the
CNS itself. Additionally, conversion of intracellular T4 into T3 by
deiodinase 2, inactivation of both T3 and T4 by deiodinase 3, and,
the ability of different TR isoforms and different coregulators to
respond directly to T4 versus T3 further regulate the CNS response
to TH. Operating together, we propose these mechanisms serve to
maintain proper endocrine homeostasis while permitting the CNS
to respond to developmental and physiological needs.
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